Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsMystery Solved: New Research Reveals Why a Key Protein Turns Deadly in Aging BodiesFebruary 26, 20252023 Spring NewsletterApril 19, 2023Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary AngioedemaJanuary 22, 2025 Previous post2026 Winter NewsletterNext postCARES Phase III clinical program did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis